Tenaya therapeutics reports first quarter 2023 financial results and provides business update

Tn-201 received fast track designation from the fda dosing complete in phase 1 clinical trial of tn-301; data expected in second half 2023 renowned researchers drs. christine seidman and alex marson join scientific advisory board announces formation of technical advisory board with deep expertise in gene therapy manufacturing south san francisco, calif.
TNYA Ratings Summary
TNYA Quant Ranking